Bio-Thera's Avastin Biosimilar Application Accepted by NMPA
China’s National Medical Products Administration (NMPA) has accepted an application for a biosimilar bevacizumab developed by Bio-Thera Solutions for treatment of certain lung and colorectal cancers.
Guangzhou, China-based Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has accepted a biologics license application (BLA) for its bevacizumab biosimilar (BAT1706).
Bio-Thera Solutions is seeking to commercially license the product referencing Genentech’s Avastin for all approved indications of the reference product in China, including advanced, metastatic, or relapsed non—small cell lung cancer, and metastatic colorectal cancer.
"Lung cancer and colorectal cancer are high-risk cancers, and patients need safe, effective, and affordable treatment drugs. BAT1706, developed in accordance with NMPA, FDA, and [European Medicines Agency] drug regulations, will provide a high-quality, low-cost treatment option for patients worldwide," Li Shengfeng, PhD, founder and CEO of Bio-Thera Solutions, said in a statement.
So far, BAT1706 has not been approved for marketing in any country.
BAT1706 demonstrated similar pharmacokinetics, efficacy, and safety compared with reference bevacizumab in a series of preclinical and clinical comparison studies.
Bevacizumab is a humanized monoclonal antibody (mAb) used to target vascular endothelial growth factor (VEGF) by binding to VEGF and blocking the binding of VEGF to its receptors. As a result, neovascularization is reduced, there is a degradation of existing blood vessels and tumor growth is inhibited.
Bio-Thera’s Growing Biosimilar Pipeline
BAT1706 is the second proposed biosimilar from Bio-Thera Solutions with positive phase 3 study results. Its first biosimlar, Qletli, a biosimilar adalimumab (Humira), received marketing approval and launched on the Chinese market in January 2020.
Bio-Thera Solutions is currently conducting phase 1 trials for its ustekinumab biosimilar (BAT2206) and its golimumab biosimilar (BAT2506). The company is also pursuing biosimilar versions of tocilizumab (Actemra) and secukinumab (Cosentyx) among others.
Increased Bevacizumab Competition
Recently, the NMPA approved Innovent Biologics’ bevacizumab biosimilar, Byvasda for all Chinese indications of the reference product.
Currently, lung cancer has the highest incidence and mortality rate in China among all malignant tumor types, with more than 770,000 newly diagnosed patients and 690,000 deaths in 2018, according to a report from the World Health Organization's International Agency for Cancer Research.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
New Year, New Hurdles: What's in Store for Biosimilars in 2023
December 18th 2022On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
November 15th 2023In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.
